Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-related Infections

Laura C. Fanucchi; Sharon L. Walsh; Alice C. Thornton; Paul A. Nuzzo; Michelle R. Lofwall

doi:10.1093/cid/ciz654

Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-related Infections

Laura C. Fanucchi, Sharon L. Walsh, Alice C. Thornton, Paul A. Nuzzo, Michelle R. Lofwall

Research output: Contribution to journal › Article › peer-review

42 Scopus citations

Abstract

In a pilot randomized trial in persons with opioid use disorder hospitalized with injection-related infections, an innovative care model combining outpatient parenteral antimicrobial therapy with buprenorphine treatment had similar clinical and drug use outcomes to usual care (inpatient intravenous antibiotic completion) and shortened hospital length of stay by 23.5 days. Clinical Trials Registration: NCT03048643.

Original language	English
Pages (from-to)	1226-1229
Number of pages	4
Journal	Clinical Infectious Diseases
Volume	70
Issue number	6
DOIs	https://doi.org/10.1093/cid/ciz654
State	Published - Mar 3 2020

Bibliographical note

Funding Information:
This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences through grant UL1TR001998.

Funding Information:
Potential conflicts of interest. L. C. F. reports travel support from the University of Vermont. M. R. L. reports consulting fees from Titan and Braeburn and research contract funding to the University of Kentucky to conduct studies funded by Braeburn. S. L. W. reports personal fees from Summit Biosciences, Otsuka, World Meds, and Brainsway; personal fees and nonfinancial support from Braeburn; personal fees and honorarium/travel support from Indivior; medication for a study from Vanda Pharmaceuticals; and travel support from Camurus outside the submitted work. All other authors report no potential conflicts.. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed.

Funding Information:
Financial support. This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences through grant UL1TR001998.

Publisher Copyright:
© 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

Keywords

antibiotics
buprenorphine
endocarditis
injection-drug use
opioid-related disorders

ASJC Scopus subject areas

Microbiology (medical)
Infectious Diseases

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1093/cid/ciz654

Cite this

@article{ced1ba9187c9439ea44ab12bb144908b,

title = "Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-related Infections",

abstract = "In a pilot randomized trial in persons with opioid use disorder hospitalized with injection-related infections, an innovative care model combining outpatient parenteral antimicrobial therapy with buprenorphine treatment had similar clinical and drug use outcomes to usual care (inpatient intravenous antibiotic completion) and shortened hospital length of stay by 23.5 days. Clinical Trials Registration: NCT03048643.",

keywords = "antibiotics, buprenorphine, endocarditis, injection-drug use, opioid-related disorders",

author = "Fanucchi, {Laura C.} and Walsh, {Sharon L.} and Thornton, {Alice C.} and Nuzzo, {Paul A.} and Lofwall, {Michelle R.}",

note = "Funding Information: This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences through grant UL1TR001998. Funding Information: Potential conflicts of interest. L. C. F. reports travel support from the University of Vermont. M. R. L. reports consulting fees from Titan and Braeburn and research contract funding to the University of Kentucky to conduct studies funded by Braeburn. S. L. W. reports personal fees from Summit Biosciences, Otsuka, World Meds, and Brainsway; personal fees and nonfinancial support from Braeburn; personal fees and honorarium/travel support from Indivior; medication for a study from Vanda Pharmaceuticals; and travel support from Camurus outside the submitted work. All other authors report no potential conflicts.. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Funding Information: Financial support. This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences through grant UL1TR001998. Publisher Copyright: {\textcopyright} 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.",

year = "2020",

month = mar,

day = "3",

doi = "10.1093/cid/ciz654",

language = "English",

volume = "70",

pages = "1226--1229",

number = "6",

}

TY - JOUR

T1 - Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-related Infections

AU - Fanucchi, Laura C.

AU - Walsh, Sharon L.

AU - Thornton, Alice C.

AU - Nuzzo, Paul A.

AU - Lofwall, Michelle R.

N1 - Funding Information: This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences through grant UL1TR001998. Funding Information: Potential conflicts of interest. L. C. F. reports travel support from the University of Vermont. M. R. L. reports consulting fees from Titan and Braeburn and research contract funding to the University of Kentucky to conduct studies funded by Braeburn. S. L. W. reports personal fees from Summit Biosciences, Otsuka, World Meds, and Brainsway; personal fees and nonfinancial support from Braeburn; personal fees and honorarium/travel support from Indivior; medication for a study from Vanda Pharmaceuticals; and travel support from Camurus outside the submitted work. All other authors report no potential conflicts.. All authors have submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Conflicts that the editors consider relevant to the content of the manuscript have been disclosed. Funding Information: Financial support. This work was supported by the National Institutes of Health National Center for Advancing Translational Sciences through grant UL1TR001998. Publisher Copyright: © 2019 The Author(s) 2019. Published by Oxford University Press for the Infectious Diseases Society of America. All rights reserved. For permissions, e-mail: journals.permissions@oup.com.

PY - 2020/3/3

Y1 - 2020/3/3

N2 - In a pilot randomized trial in persons with opioid use disorder hospitalized with injection-related infections, an innovative care model combining outpatient parenteral antimicrobial therapy with buprenorphine treatment had similar clinical and drug use outcomes to usual care (inpatient intravenous antibiotic completion) and shortened hospital length of stay by 23.5 days. Clinical Trials Registration: NCT03048643.

AB - In a pilot randomized trial in persons with opioid use disorder hospitalized with injection-related infections, an innovative care model combining outpatient parenteral antimicrobial therapy with buprenorphine treatment had similar clinical and drug use outcomes to usual care (inpatient intravenous antibiotic completion) and shortened hospital length of stay by 23.5 days. Clinical Trials Registration: NCT03048643.

KW - antibiotics

KW - buprenorphine

KW - endocarditis

KW - injection-drug use

KW - opioid-related disorders

UR - http://www.scopus.com/inward/record.url?scp=85081126411&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85081126411&partnerID=8YFLogxK

U2 - 10.1093/cid/ciz654

DO - 10.1093/cid/ciz654

M3 - Article

C2 - 31342057

AN - SCOPUS:85081126411

SN - 1058-4838

VL - 70

SP - 1226

EP - 1229

JO - Clinical Infectious Diseases

JF - Clinical Infectious Diseases

IS - 6

ER -

Outpatient Parenteral Antimicrobial Therapy Plus Buprenorphine for Opioid Use Disorder and Severe Injection-related Infections

Abstract

Bibliographical note

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this